Cellavision Ab Stock Performance
| CLVSF Stock | USD 16.83 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.19, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CellaVision are expected to decrease at a much lower rate. During the bear market, CellaVision is likely to outperform the market. At this point, CellaVision AB has a negative expected return of -0.19%. Please make sure to confirm CellaVision's standard deviation, skewness, as well as the relationship between the Skewness and relative strength index , to decide if CellaVision AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days CellaVision AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 102.3 M | |
| Total Cashflows From Investing Activities | -84.3 M |
CellaVision |
CellaVision Relative Risk vs. Return Landscape
If you would invest 1,928 in CellaVision AB on September 30, 2025 and sell it today you would lose (245.00) from holding CellaVision AB or give up 12.71% of portfolio value over 90 days. CellaVision AB is currently producing negative expected returns and takes up 1.6711% volatility of returns over 90 trading days. Put another way, 15% of traded pink sheets are less volatile than CellaVision, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CellaVision Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CellaVision's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as CellaVision AB, and traders can use it to determine the average amount a CellaVision's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.116
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLVSF |
Based on monthly moving average CellaVision is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CellaVision by adding CellaVision to a well-diversified portfolio.
CellaVision Fundamentals Growth
CellaVision Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CellaVision, and CellaVision fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CellaVision Pink Sheet performance.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.19 % | |||
| Current Valuation | 600.98 M | |||
| Shares Outstanding | 23.85 M | |||
| Price To Earning | 46.79 X | |||
| Price To Book | 9.14 X | |||
| Price To Sales | 8.50 X | |||
| Revenue | 565.55 M | |||
| EBITDA | 193.6 M | |||
| Cash And Equivalents | 18.51 M | |||
| Cash Per Share | 0.78 X | |||
| Debt To Equity | 0.20 % | |||
| Book Value Per Share | 1.22 X | |||
| Cash Flow From Operations | 159.72 M | |||
| Earnings Per Share | 0.50 X | |||
| Total Asset | 825.21 M | |||
About CellaVision Performance
By analyzing CellaVision's fundamental ratios, stakeholders can gain valuable insights into CellaVision's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CellaVision has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CellaVision has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CellaVision AB develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. CellaVision AB was incorporated in 1994 and is headquartered in Lund, Sweden. Cellavision is traded on OTC Exchange in the United States.Things to note about CellaVision AB performance evaluation
Checking the ongoing alerts about CellaVision for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CellaVision AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CellaVision AB generated a negative expected return over the last 90 days | |
| About 38.0% of the company shares are held by company insiders |
- Analyzing CellaVision's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CellaVision's stock is overvalued or undervalued compared to its peers.
- Examining CellaVision's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CellaVision's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CellaVision's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CellaVision's pink sheet. These opinions can provide insight into CellaVision's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CellaVision Pink Sheet analysis
When running CellaVision's price analysis, check to measure CellaVision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CellaVision is operating at the current time. Most of CellaVision's value examination focuses on studying past and present price action to predict the probability of CellaVision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CellaVision's price. Additionally, you may evaluate how the addition of CellaVision to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |